Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note published on Thursday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

EVOK stock opened at $2.82 on Thursday. The firm’s fifty day simple moving average is $4.40 and its 200-day simple moving average is $4.67. The company has a market capitalization of $4.21 million, a P/E ratio of -0.26 and a beta of 0.12. Evoke Pharma has a 12 month low of $2.50 and a 12 month high of $12.32.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings data on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.24). Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%. The business had revenue of $3.31 million during the quarter, compared to analysts’ expectations of $3.08 million.

Hedge Funds Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. bought a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) in the 3rd quarter, according to its most recent filing with the SEC. The fund bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma at the end of the most recent reporting period.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.